Atezolizumab Biosimilar - Ultra Low Endotoxin

Human

PD-L1

>1mg/ml

Human IgG1 Kappa

Humanized

Anti-Mouse PD-L1 (10F.9G2) In Vivo Antibody - Low Endotoxin (ICH1086), Mouse Anti-Mouse PD-L1 (10F.9G2) Recombinant Antibody (ICH1183), Anti-Human PD-L1 (29E.2A3) In Vivo Antibody - Low Endotoxin (ICH1221), Avelumab Biosimilar - Research Grade (ICH4017), Durvalumab Biosimilar - Research Grade (ICH5005), Envafolimab Biosimilar - Research Grade (ICH5177), Benmelstobart Biosimilar - Research Grade (ICH5388), Betifisolimab Biosimilar - Research Grade (ICH5397), Cemavafusp Biosimilar - Research Grade (ICH5431), Cosibelimab Biosimilar - Research Grade (ICH5451), Danburstotug Biosimilar - Research Grade (ICH5464), Garivulimab Biosimilar - Research Grade (ICH5565), Lesabelimab Biosimilar - Research Grade (ICH5635), Manelimab Biosimilar - Research Grade (ICH5667), Opucolimab Biosimilar - Research Grade (ICH5740), Pacmilimab Biosimilar - Research Grade (ICH5752), Socazolimab Biosimilar - Research Grade (ICH5870), Sudubrilimab Biosimilar - Research Grade (ICH5885), Tagitanlimab Biosimilar - Research Grade (ICH5895)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

Q9NZQ7

29126

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of atezolizumab, a fully human IgG1 kappa antibody built around the immune checkpoint ligand PD-L1 (CD274, UniProt Q9NZQ7). It is supplied for research use only (RUO) and is not the clinical drug, nor is it intended for human or veterinary use. Like the originator, this analog binds the human PD-L1 ectodomain and blocks the PD-L1/PD-1 and PD-L1/B7-1 (CD80) interactions, making it a convenient tool for interrogating checkpoint biology in vitro. The originator carries an engineered aglycosylated Fc that reduces FcgammaR engagement and ADCC; researchers evaluating effector function should confirm the Fc characteristics of any given lot. Typical research applications include positive/reference controls in blockade assays, epitope and binding studies, PD-L1 detection reagents, and biosimilar comparability work. It is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay standardization, reproducibility, and larger preclinical and in-vitro screening campaigns. PD-L1 (programmed death-ligand 1; CD274, B7-H1) is a type I transmembrane glycoprotein of the B7 immunoglobulin superfamily. It is expressed on many cell types, including antigen-presenting cells, epithelial and endothelial cells, and is frequently upregulated on tumor cells and within the tumor microenvironment, often driven by interferon-gamma. PD-L1 is the principal ligand for the inhibitory receptor PD-1 (PDCD1) on activated T cells; engagement delivers a co-inhibitory signal that dampens T-cell receptor signaling, cytokine production, and proliferation, contributing to peripheral tolerance and, in cancer, immune evasion. PD-L1 also binds B7-1 (CD80) in cis and in trans, further modulating T-cell responses. Blocking the PD-L1/PD-1 axis relieves this inhibition and can restore antitumor T-cell activity, the rationale underlying checkpoint-blockade immunotherapy.

Programmed cell death 1 ligand 1, Cd274, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, PDL-1

Detects human PDL-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atezolizumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0009

Atezolizumab (anti-PD-L1) Biosimilar - Ultra Low Endotoxin

Q: Is the Atezolizumab biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Atezolizumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Atezolizumab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Atezolizumab that binds human PD-L1; for research use only (RUO).